Ferring Ventures

Also known as: Ferring Ventures S.A., Ferring Ventures, Ferring Ventures SA

Data updated June 29, 2026

St-Prex, Vaud, Switzerland

Ferring Ventures is an investment vehicle associated with Ferring's broader life-science and biopharmaceutical platform in Switzerland. Public and registry materials tie the entity to St-Prex and place it within a larger organization focused on therapeutic innovation and commercialization.

Ferring Ventures matters for psychedelic coverage because it shows strategic corporate capital entering the space through atai-linked financings in 2025. That makes it more relevant than a passive one-off holder, while still leaving it outside the category of dedicated psychedelic investors.

Investor Context

Investment Context

This stakeholder is listed as a Strategic Corporate Investor. Its public geography context is global. Public stage signals include Growth / Late Stage and Multi-Stage. Public focus areas include Drug Development and Manufacturing & Supply Chain.

Public Portfolio Examples

AtaiBeckleyConcurrent private placement - $30.0M - Jun 2, 2025
atai Life SciencesPrivate placement financing - approximately $50 million - Jul 1, 2025

Ferring Ventures is best framed as strategic corporate healthcare capital with atai/AtaiBeckley financing exposure. Its public record supports psychedelic-adjacent drug-development relevance, not a broader standalone psychedelic portfolio thesis.

Investor Type

Strategic Corporate Investor

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

Growth / Late StageMulti-Stage

Investment Focus Areas

Drug DevelopmentManufacturing & Supply Chain